Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could take the edge off social anxiety on the spot

NCT ID NCT06510504

Symptom relief Sponsor: Bionomics Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single dose of BNC210 can quickly reduce anxiety in people with social anxiety disorder. 370 adults took either the drug or a placebo before a public speaking challenge and rated their distress. The goal is to see if BNC210 works as an as-needed treatment for social anxiety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BNC210
What this could lead to
If successful, BNC210 could offer a fast-acting, on-demand option to ease anxiety during social situations like public speaking.
What could go wrong
This is a completed Phase 3 trial, but results are not yet public. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

370 people

The number who actually took part.

Started

Aug 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A current diagnosis of social anxiety disorder as defined in the DSM-5. * A Liebowitz Social Anxiety Scale total score of ≥60. * Suitable contraception use in line with protocol requirements. * Ability to swallow tablets. Exclusion Criteria: * History of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorders, anorexia or bulimia, body dysmorphic disorder, PTSD, autism-spectrum disorder or obsessive-compulsive disorder, or any other Axis I or II disorder which is currently the primary focus of treatment over social anxiety disorder. * Hamilton Rating Scale for Depression score of ≥18. * Moderate or severe alcohol-use disorder, or any other substance-use disorder (any severity) in the past 12 months. * Use of psychotropic medications within 30 days of screening. Daily use of benzodiazepines within 90 days of screening. * Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Social anxiety disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

social phobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Social anxiety disorder

Contacts and locations

Locations

  • AFFIRM-1 Study Site

    Encino, California, 91316, United States

  • AFFIRM-1 Study Site

    La Jolla, California, 92037, United States

  • AFFIRM-1 Study Site

    Los Angeles, California, 90025, United States

  • AFFIRM-1 Study Site

    Oceanside, California, 92056, United States

  • AFFIRM-1 Study Site

    San Diego, California, 92103, United States

  • AFFIRM-1 Study Site

    San Jose, California, 95124, United States

  • AFFIRM-1 Study Site

    Sherman Oaks, California, 91403, United States

  • AFFIRM-1 Study Site

    Temecula, California, 92591, United States

  • AFFIRM-1 Study Site

    Jacksonville, Florida, 32256, United States

  • AFFIRM-1 Study Site

    Lauderhill, Florida, 33319, United States

  • AFFIRM-1 Study Site

    Miami Lakes, Florida, 33016, United States

  • AFFIRM-1 Study Site

    Orlando, Florida, 32801, United States

  • AFFIRM-1 Study Site

    Tampa, Florida, 33607, United States

  • AFFIRM-1 Study Site

    Decatur, Georgia, 30030, United States

  • AFFIRM-1 Study Site

    Boston, Massachusetts, 02114, United States

  • AFFIRM-1 Study Site

    Boston, Massachusetts, 02131, United States

  • AFFIRM-1 Study Site

    Princeton, New Jersey, 08540, United States

  • AFFIRM-1 Study Site

    Brooklyn, New York, 11229, United States

  • AFFIRM-1 Study Site

    Charlotte, North Carolina, 28211, United States

  • AFFIRM-1 Study Site

    Media, Pennsylvania, 19063, United States

  • AFFIRM-1 Study Site

    Austin, Texas, 78737, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.